Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hana Biosciences has begun a phase I clinical trial of its developmental drug IPdR as a treatment for a number of different cancers.
Subscribe to our email newsletter
The objectives of this clinical trial are to establish the safety, dose and preliminary efficacy of IPdR in combination with radiation therapy in colorectal, gastric, pancreatic and liver cancers.
IPdR demonstrated a survival advantage in phase II studies in anaplastic astrocytoma, a type of brain tumor. Preclinical studies have also demonstrated that IPdR has dose responsive and synergistic effects when combined with radiation in human glioblastoma models.
Hana Biosciences licensed IPdR from Yale University and The Research Foundation of the State University of New York at Buffalo. IPdR is initially being developed for the treatment of colorectal, gastric, liver, and pancreatic cancers. In addition, a phase I/II clinical trial into a type of brain cancer, is planned.
“IPdR is a promising oral compound that builds on the well-defined mechanism of action and proven utility of intravenously-administered IUdR,” stated Dr Timothy Kinsella, professor and chairman of the department of radiation oncology at Case Western Reserve University in Ohio.